Establishing a new target range for unfractionated heparin for acute coronary syndromes

Journal of Thrombosis and Thrombolysis

Volumn 17, Issue 2, 2004, Pages 121-126

  Lee, Michael S ^a   Menon, Venu ^a   Schappert, Joseph ^a   Wilentz, James R ^a   Singh, Varinder ^a   Hochman, Judith S ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; THROMBOPLASTIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; OUTCOMES RESEARCH; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; STANDARDIZATION;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; FACTOR XA; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; REFERENCE VALUES; REGRESSION ANALYSIS;

EID: 4344693284     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:THRO.0000037667.52940.64     Document Type: Article

References (44)

1. Ambrose JA, Winters SL, Arora RR, et al. Angiographic evaluation of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986 7:474-478.
2. Williams AE, Freeman AM, Chisolm RJ, Patt NL, Armstrong PW. Angiographic morphology in unstable angina pectoris. Am J Cardiol 1988 62:1024-1027.
3. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995 92:657-671.
4. Fuster V, Badimon L, Badimon JJ, Cheseboro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Eng J Med 1992;36:310-318.
5. Vetrovec G, Leinback R, Gold HK, Cowley MJ. Intracoronary thrombolysis in syndromes of unstable angina: Angiographic and clinical results. Am Heart J 1982;104:946-952.
6. Mandelkorn J, Wolf N, Singh S, et al. Intracoronary thrombus in nontransmural myocardial infarction and in unstable angina pectoris. Am J Cardiol 1983;52:1-6.
7. Sherman CT, Litvack F, Gundfest T, et al. Coronary angioscopy in patients with unstable angina pectoris. N Eng J Med 1986;315:913-919.
8. Mizuno K, Satomora K, Miyamoto A, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1992;326:287-291.
9. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both o treat acute unstable angina. N Engl J Med 1988;319:1105-1111.
10. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
11. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998 338:1498-1505.
12. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
13. Gawoski J, Arkin CF, Bovill T, Brandt JT, Rock WA Jr, Triplett DA. The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists survey specimens: Responsiveness, precision, and sample effects. Arch Pathol Lab Med 1987;111:785-790.
14. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina, non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee of the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000;36:970-1062.
15. Gawoski J, Arkin CF, Bovill T, et al. The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists survey specimens: Responsiveness, precision, and sample effects. Arch Pathol Lab Med 1987;111:785-790.
16. Bain B, Forster T, Sleigh B. Heparin and the activated partial thromboplastin time-a difference between the in-vitro and in-vivo effects and implications for the therapeutic range. Am J Clin Pathol 1980 ;74:668-673.
17. Zanke B, Shojania AM. Comparison of two APTT methods of monitoring heparin therapy. APTT ratio and heparin response of pooled normal plasma. Am J Clin Pathol 1990;93:684-689.
18. Scalla SJ. Heparin monitoring by activated partial thromboplastin time. Comparison of ex vivo measurement and in vitro standardization. Am J Clin Pathol 1985;84:351-354.
19. van den Besselaar AM, Meeuwisse-Braun J, Bertina RM. Monitoring heparin therapy: Relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost 1990;63:16-23.
20. Shojania AM, Tetreault J, Turnbull G. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol 1988 89:19-23.
21. Poller L, Hirsh J. Special report: A simple system for the derivation of international normalized ratios for the reporting of prothrombin time results with North American thromboplastin reagents. Am J Clin Pathol 1989;92:124-1266.
22. Braunwald E. Mark DB, Jones RH, et al. Unstable angina: Diagnosis and management. Clinical Practice Guideline No. 10. Rockville, MD: Agency for Health Care Policy and Research, 1994. (AHCPR Publication No. 94-0602).
23. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat unstable angina. N Eng J Med 1988;319:1105-1111.
24. Theroux P, Waters D, Qui S, McCans J, deGuise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88:2045-2048.
25. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-830.
26. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in non-prior aspirin users: Primary end points analysis from the ATACS trial. Circulation 1994;89:81-88.
27. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
28. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: A meta-analysis. JAMA 1996;276:811-815.
29. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104-109.
30. Hirsch J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest 2001; 119:64S-93S.
31. Menon V, Berkowitz SD, Antman EM, Fuchs RM, Hochman JS. New heparin dosing recommendations for patients with acute coronary syndromes. Am J Med 2001;110:641-650.
32. Bates SM, Weitz JI, Johnston M, Hirsch J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range of unfractionated heparin. Arch Intern Med 2001;161:385-391.
33. Mesters RM, Mikoteit T, Schiller M, Krings W, Ostermann H, Kienast J. Markers of coagulation activation for evaluation of the antithrombotic efficacy of heparin: A prospective study in acute deep venous thrombosis. Blood Coagul Fibrinolysis 1995;6:665-671.
34. Young E, Pruis M, Levine MN, et al. Heparin building to plasma proteins: An important mechanism for heparin resistance. Thromb Haemost 1992;67:639-643.
35. Hirsh J, Van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976 53:691-695.
36. Levine MN, Hirsh J. Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56.
37. Aiach M, Michaud A, Balian JL, et al. A new low molecular weight heparin derivative, in vitro and in vivo studies. Thromb Res 1983 31:611-621.
38. Bara L, Billand E, Gramond G, et al. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985;39:631-636.
39. Turpie AGG. Can we differentiate the low-molecular weight heparins? Clin Cardiol 2000;23(Suppl I):14-17.
40. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-452.
41. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B. Circulation 1999;100:1593-1601.
42. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-327.
43. Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977;49:171-184.
44. Levine MN, Hirsh J, Gent, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56.